European Pharmaceutical Review

JULY 11, 2023

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) has highlighted the importance of post-approval R&D in advancing oncology treatment options and delivering unprecedented progress over the past ten years. This therefore broadens the population of patients who may benefit.

Food and Drug Administration 74

Food and Drug Administration Medicine Pharmaceutical research FDA 74

Pharmaceutical Technology

MAY 17, 2023

The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drug pricing provisions. At the core of the debate was a new provision allowing the US Centers for Medicare & Medicaid Services (CMS) to negotiate prices with pharmaceutical companies for a select number of drugs.

Food and Drug Administration 52

Food and Drug Administration Pharma Patients Pharmaceutical research 52

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

Pharmaceutical Technology

FEBRUARY 13, 2023

However, there is a high level of attrition during the pharmaceutical research and development process, which is an indicator of the vast number of potential drug substances considered for progression. Therefore, it is vital to choose molecules for pharmaceutical development very carefully.

Food and Drug Administration 52

Food and Drug Administration Leads Pharmaceutical Pharmaceutical research 52

PM360

NOVEMBER 12, 2024

They are difficult to diagnose early in a disease, the regulatory endpoints are often unprecedented and challenging, and many drugs struggle to get into the brain. The downside is that it also keeps most potential drug treatments from reaching the brain. Patients are waiting! But innovation doesn’t stop in the lab.

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Healthcare Healthcare 52

Pharmaceutical Technology

APRIL 12, 2023

Pharmaceutical research has long relied on non-human primate models for early-stage discoveries, but their use continues to cause controversy. However, according to the US Food and Drug Administration (FDA), non-human primates are still the most scientifically relevant large model to test biologic drugs for safety.

Pharma 98

Pharma Food and Drug Administration Safety Medicine 98